NationalTop Headlines

Beijing kicks off mass vaccination for key groups amid concerns on Phase 3 clinical trial data

Beijing has started mass vaccination program amid concerns regarding its efficacy owing to the absence of phase 3 clinical trial data.

Beijing has started mass vaccination program amid concerns regarding its efficacy owing to the absence of phase 3 clinical trial data.

Beijing Municipal Health Commission said at a news conference on Sunday that more than 70000 people in 220 inoculation venues across Beijing have received the first dose of COVID-19 vaccine since the city began administering the jab among specific groups of people with higher infection risks on the first day of new year 2021.

There are, however, strong concerns in the global medical community about the safety and efficacy of the Chinese vaccines. Chinese Foreign Ministry last week said, phase three trials are going smoothly, without giving a clear response on when China is planning to release the phase 3 clinical trial data.

China announced Thursday that it had granted conditional marketing authorization to its first self-developed COVID-19 vaccine. The inactivated vaccine was developed by the Beijing Biological Products Institute Co. Ltd. under Sinopharm’s subsidiary China National Biotec Group (CNBG).

Tags

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Back to top button